... cont'd 1/2

* regulator protein CMTM6 inhibits degradation of bothCD58 (which stimulates T cell activity) & cell surface protein PD-L1 (which inhibits T cell activity)

* CD58 & PD-L1 compete for binding to regulator protein CMTM6

* tumor cell that express less CD58 free up more CMTM6 to stabilize PD-L1

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity

https://www.sciencedirect.com/science/article/abs/pii/S1535610823001812

https://www.biorxiv.org/content/10.1101/2022.03.21.485049v1

* cancer immune evasion

...